-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company,
CAMPBELL, Calif. and CHARLOTTE, N.C., May 15, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, and HarborPath Direct, Inc. , today announced a partnership to facilitate access to PANCREAZE ® (pancrelipase) Delayed Release Capsules for uninsured or
March 14, 2019 (ACCESSWIRE via COMTEX) -- CAMPBELL, CA / ACCESSWIRE / March 14, 2019 / VIVUS, Inc. VVUS, -1.41% a biopharmaceutical company, today announced that the Ministry of Health of the Russian Federation has approved 50 mg, 100 mg and 200 mg tablets of avanafil for the treatment of erectile
-Study finds no increase in risk for major adverse cardiovascular events for individuals currently using phentermine in combination with topiramate; study adds to robust data supporting the safety and efficacy of Qsymia- CAMPBELL, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc.
-Fundraising event at AT&T Stadium on September 22 supports the Dallas-Fort Worth chapter of the Cystic Fibrosis Foundation - CAMPBELL, Calif. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that it is supporting the
-Retrospective analysis presented at the 34 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management - CAMPBELL, Calif. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, has reported encouraging data from a
-Favorable pharmacokinetic results add to body of data supporting continued development in the treatment of pulmonary arterial hypertension- CAMPBELL, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced positive
CAMPBELL, Calif. , June 11, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced that it has met the closing conditions, including Hart-Scott-Rodino review, related to the Company’s previously announced acquisition of U.S.
Attains key milestone under strategic focus on building a broad portfolio of cash flow-generating products CAMPBELL, CA., May 1, 2018 – VIVUS, Inc. (N asdaq : VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into a definitive agreement to acquire all product
Board Member Thomas B. King appointed interim CEO; Seth Fischer steps down as CEO effective December 31, 2017 CAMPBELL, CA -- (Marketwired) -- 12/26/17 -- VIVUS, Inc. (NASDAQ: VVUS) today announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as chief
